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Human pluripotent stem cells (hPSCs) derived from either blastocyst stage embryos (hESCs) or reprogrammed somatic cells
(iPSCs) can provide an abundant source of human neuronal lineages that were previously sourced from human cadavers, abortuses,
and discarded surgical waste. In addition to thewell-known potential therapeutic application of these cells in regenerativemedicine,
these are also various promising nontherapeutic applications in toxicological and pharmacological screening of neuroactive
compounds, as well as for in vitro modeling of neurodegenerative and neurodevelopmental disorders. Compared to alternative
researchmodels based on laboratory animals and immortalized cancer-derived humanneural cell lines, neuronal cells differentiated
from hPSCs possess the advantages of species specificity together with genetic and physiological normality, which could more
closely recapitulate in vivo conditionswithin the human central nervous system.This review critically examines the various potential
nontherapeutic applications of hPSC-derived neuronal lineages and gives a brief overview of differentiation protocols utilized to
generate these cells from hESCs and iPSCs.
1. Introduction
The term of human pluripotent stem cells (hPSCs) is an
umbrella term that encompasses both human embryonic
stem cells (hESCs) [1] and human induced pluripotent stem
cells (hiPSCs) [2]. The distinct advantages that these cells
have over adult stem cells are their unlimited proliferative
capacity and much more extensive differentiation potential
[1, 2]. As such, neural differentiation of PSCs could provide
a promising cell source for regenerative medicine and cell
therapy applications [2], for in vitro pharmacological and
toxicological screening of neuroactive compounds [3, 4], as
well as in vitromodeling of neurodegenerative and neurode-
velopmental diseases [5].
Utilization of hESCs is ethically controversial because
it involves the destruction of human embryos. Therefore,
one way to circumvent these ethical issues is to reprogram
somatic cells to iPSCs via recombinant expression of specific
transcription factors such as OCT3/4, SOX2, KLF4, and
c-MYC [6, 7]. Currently, it is generally accepted in the
scientific community that hiPSCs are highly similar if not
virtually identical to hESCs in terms of their morphology,
surface marker expression, feeder dependence, and in vivo
teratoma formation capacity [6, 8]. Various adult somatic cell
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types have been used to generate iPSCs such as hair follicle
progenitors, bone marrow stromal cells, lymphocytes, skin
biopsy, and even epithelial cells from the urinary tract [6, 9–
12].
Because neural differentiation of hPSCs for therapeu-
tic applications in regenerative medicine has already been
extensively reviewed in the scientific literature, this review
will give a brief overview of current protocols for neural
differentiation of hPSCs followed by examination of the
various nontherapeutic applications of hPSCs-derived neural
lineages, in particular for in vitro toxicological and pharma-
cological screening of neuroactive compounds, as well as for
in vitro modeling of neurodegenerative and neurodevelop-
mental diseases.
2. Neural Differentiation of hPSCs: Progress
towards a Defined Culture Milieu and Small
Molecule Inducers
The unlimited self-renewal capacity and proliferative poten-
tial of hPSCs offer great promise to both basic research and
translational clinical applications as an inexhaustible and
replenishable cell source. Nevertheless at the undifferentiated
pluripotent stage, these cells cannot be deployed directly
into patients due to their tumorigenic potential [13]. Thus,
establishment of efficient stepwise differentiation protocols
for directing hPSCs into specific cell lineages is an essential
prerequisite for both therapeutic and basic research applica-
tions.
Previously, two conventional techniques commonly uti-
lized to initiate neural differentiation of hPSCs are embryoid
body (EB) formation (from dissociated suspension culture)
and cocultivation with stromal cell lines [14]. However, these
approaches are complicated, time consuming, and ineffective,
yielding great variability in results. Alternative commercial
good manufacturing practice- (GMP-) compliant neural
induction mediums and kits are emerging despite the high
costs. Significant progress has been made in developing
protocols for efficient neural differentiation of hPSCs, and the
current trend gravitates towards chemically defined culture
milieu supplemented with small molecule inducers of neural
differentiation.The use of small molecules is highly desirable
because it is cost effective and stable and reduces experimen-
tal variability [15]. Moreover, the biological effects of small
molecules are rapid, reversible, and tuneable by varying the
concentration or duration of exposure. Many studies have
demonstrated the significant benefits of a small molecule-
based system for stem cell differentiation. We therefore
emphasize here recent strategies using small molecules for
neural induction of hPSCs.
Neural differentiation of hPSCs generally relies on the
interplay of activation and inhibition of multiple devel-
opmental signalling pathways tightly controlled by growth
factors, cytokines, and epigenetics mechanisms. Improved
understanding of developmental signalling pathways has
guided the design of neural differentiation protocols. An
increasing number of studies have illustrated the use of small
molecules to modulate the key developmental signalling
pathways known to regulate neural differentiation of hPSCs.
Chambers and colleagues demonstrated that the combined
use of multiple small molecule signalling pathway inhibitors,
including LDN 193189, SB 431542, SU 5402, CHIR99021,
and DAPT could accelerate the neural differentiation of
hPSCs [16]. Neely et al. [17] showed that a newly developed
highly selective small molecule BMP-inhibitor, DMH-1, can
effectively induce neurogenesis of hiPSCs when combined
with SB 431542. DMH-1 is postulated to substitute the
function of commonly used but expensive growth factors.
The same study also highlighted that optimal small molecule
concentration is crucial for appropriate expression levels and
timing of activation of various transcription factors related
to neuronal lineage specification. Another study illustrated
a highly efficient protocol for directing monolayer-cultured
hESCs into homogenous primitive neural stem cells (pNSCs)
with combined inhibition of the GSK3, TGF-𝛽, and Notch
signalling pathways [18]. Long-term expansion culture of
pNSCs with a cocktail of leukaemia inhibitory factor (LIF),
CHIR 99021, and SB 431542 retained remarkably high
neurogenic propensity and plasticity [18]. The same study
also revealed that the addition of a 𝛾-secretase inhibitor
(compound E) induced rapid neural differentiation. Such an
approach enables controlled expansion of the desired neural
precursor populations and overcomes the limitations of the
directed differentiation process, which often yields heteroge-
neous neural populations.
More recently, studies on small molecule inducers of
neuronal differentiation have focused on directing hPSCs
into each of the four major specific neuronal sublineages,
that is, dopaminergic, serotonergic, GABAergic, and cholin-
ergic/motor neurons. This is because many neurodegener-
ative diseases are characterized by the dysfunction or loss
of specific neuronal sublineages. For example, Parkinson’s
disease is characterized by dysfunction/loss of dopaminergic
neurons [19, 20], while Alzheimer’s disease on the other hand
is thought to arise from the dysfunction/loss of cholinergic
neurons [21]. It is well known that Huntington’s disease is
characterized by the degeneration of GABAergic medium-
sized spiny neurons (MSNs) [22], while amyotrophic lateral
sclerosis is characterized by the degeneration of cholinergic
motor neurons [23]. Hence, there is much interest in devel-
oping small-molecule based differentiation protocols for
deriving specific neuronal sublineages from hPSCs (Table 1),
for in vitro modeling of neurodegenerative diseases, as well
as for pharmacological screening of new drugs to treat these
diseases.
Chambers and colleagues developed a protocol for dif-
ferentiation of hPSCs into dopaminergic neurons, using dual
inhibition of SMAD signals [24]. This was based on previous
knowledge that the endogenous bone morphogenic protein
(BMP) antagonist, noggin, is a critical neural-inducer in
frog [31, 32] and that inhibition of Activin/Nodal/TGF𝛽
signalling by the small molecule SB 431542 (Activin A
receptor-like kinase ALK4, 5, 7 inhibitor) has been shown
to enhance neural induction of hESCs [33]. This dual-SMAD
inhibition protocol bypassed EB formation and yielded over
80% neural induction efficiency [24]. The study of Kriks
et al. [25] also utilized a dual SMAD inhibition protocol
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Table 1: Small-molecule based culture protocols for inducing hPSCs differentiation into specific neuronal sublineages.
Neuronal sublineages Key references Small molecules utilized
Dopaminergic
Chambers et al. [24] SB431542(together with the protein noggin)
Kriks et al. [25]
Purmorphamine + CHIR99021
(together with the growth factor FGF8 and recombinant
sonic hedgehog)
Mak et al. [26] Dorsomorphin + SB431542
GABAergic Samarasinghe et al. [27] Agonists of muscarinic and GluR1 receptor
Cholinergic motor neurons
Li et al. [28] Retinoic acid + purmorphamine
Hu and Zhang [29] Retinoic acid + purmorphamine
Amoroso et al. [30] Retinoic acid + purmorphamine + SMO agonist SAG
to derive dopaminergic neurons from human embryonic
stem cells, by utilizing the small molecules purmorphamine
and CHIR99021, together with FGF8 and recombinant sonic
hedgehog (SHH C25II). In another study by Mak et al. [26],
dopaminergic neurons were derived from six hiPSCs lines of
patientswith Parkinson’s disease, utilizing dorsomorphin that
had BMP-antagonistic activities similar to noggin. Neural
precursors were derived with a 5-stage embryoid body differ-
entiation protocol, using a combination of dorsomorphin and
SB431542, with neuronal maturation achieved by substituting
sonic hedgehog (SHH) with purmorphamine or smoothened
agonist.
To date, the only reported study on the use of small
molecules for directing hPSCs differentiation into GABAer-
gic neurons involved combined transient stimulation of
muscarinic and GluR1 receptors with their respective small
molecule agonists [27]. Although there was inhibition of
overall neurogenesis, enhanced differentiation into immature
GABAergic neurons was observed. Other studies utilizing
protein-based growth factors have reported that Activin A
[34], Sonic Hedgehog (SHH), and DKK1 protein [35, 36]
could drive PSCs differentiation into GABAergic neurons. It
is probable that, in the future, these protein-based growth
factors could be substitutedwith smallmolecules that activate
similar signaling pathways.
Currently, there have yet been no reported studies on
small molecule induction of serotonergic neurons from
PSCs. However, noggin has been reported to enhance mouse
embryonic stem cell differentiation into serotonergic neurons
[37, 38]. It is possible that small molecules eliciting similar
signalling pathways as noggin could enhance hPSCs differ-
entiation into serotonergic neurons.
A number of studies have reported that retinoic acid in
combination with purmorphamine that activates the sonic
hedgehog signaling pathway could induce hPSCs differenti-
ation into cholinergic motor neurons [28, 29]. Amoroso and
colleagues [30] further reported that a third small molecule,
SMO agonist SAG, could also be used in combination with
retinoic acid and purmorphamine for induction of choliner-
gic motor neurons from PSCs. In another study on mouse
embryonic stem cells by Wang et al. [39], it was reported
that the small molecule icaritin could also induce hPSCs
differentiation into cholinergic motor neurons, but this has
yet to be tested on hPSCs.
In conclusion, synthetic small molecules are powerful
tools for manipulation of stem cell lineage fate and differ-
entiation pathways, and they also provide deep insights into
the underlying molecular mechanisms that control stem cell
fate. Nonetheless, more potent and specific small molecules
are required for precise control of neurogenesis. Continu-
ous characterization of small molecules and comprehensive
understanding of the underlying molecular mechanisms
are necessary for achieving greater efficiency in the neural
differentiation of hPSCs. More recently, Wen and Jin [40]
developed a robust protocol that efficiently yields NSCs
from hPSCs without utilising either small molecules or the
EB formation step. The generated NSCs retained the same
differentiation capacity as that derived by the EB formation
approach. It was hypothesized that a dynamic change of cell-
substrate matrix interactions via a short suspension culture
led to ectoderm lineage specification by hPSCs, even though
the underlying mechanisms remain uncharacterized.
3. Nontherapeutic Applications of
Human Pluripotent Stem Cells-Derived
Neural Lineages
Neuroscience research has advanced at a rapid pace over
the past few decades, yet it remains as one of the greatest
challenges in the 21st century. The functioning of the human
brain remains enigmatic and very few research discoveries
have been translated into the development of innovative
treatment for neurological disorders and diseases, despite the
best collaborative efforts of academic research institutions
and the biopharmaceutical industry [41].
This could be because our understanding of neurodevel-
opment and neurological disease pathophysiology has been
severely hampered by the relative inaccessibility of human
brain tissues. It is often difficult to obtain neural tissue sam-
ples from a live human brain for disease modeling, molecular
analysis, and drug screening. Until recently, most of the
published data in neuroscience research was based on animal
models, transformed cell lines, and tissues from aborted
foetuses or discarded poor-quality pathological samples from
brain surgery patients [42]. Although these have undoubtedly
made valuable contributions in deciphering neurodevelop-
mental mechanisms, as well as in providing insights into
4 Stem Cells International
the pathogenesis of neurological disorders and the roles of
specific genes in neurodegeneration, it must nevertheless
be noted that the experimental data obtained from animals
and transformed cell lines are often not representative of
human neurological function due to greater complexity of
the human brain and interspecies physiological differences.
In addition, neurons from different species may exhibit
different electrophysiological properties [43], and neural
tissues sourced from foetuses or surgery are extremely rare.
Given these limitations, there is a dire need for alternative
sources of human neural tissues that are readily available and
physiologically relevant.
The discovery of both hESCs and hiPSCs could provide
new tools to study neural development and neurological dis-
eases mechanisms in vitro, as well as for screening and devel-
opment of new drugs for neurological disorders. Neuronal
lineages derived from hPSCs provide distinct advantages
over other model systems as they are more representative
of human neural physiology and can accurately recapitulate
the in vivo conditions of neurodegenerative diseases in vitro,
hence overcoming the problem of species specificity. This
in turn has led to increased adoption of hPSCs models
by neuroscience researchers for pathological modeling, tox-
icology assessment, and drug screening. In addition, the
biopharmaceutical industry has begun to embrace the human
pluripotent stem cell-based approach for drug development
and predictive toxicology assays [44].
4. Toxicology
The human body is constantly being exposed to potential
neurotoxic compounds in daily life, ranging from contam-
inating pesticides on vegetables to the veritable menagerie
of industrial chemicals found in human consumer products.
A large number of these pose serious health hazards to
the human nervous system, yet little is known about how
exposure to compounds will impact human neural function
and development.There is a dire lack of neurotoxicity data on
the various compounds that we are being exposed on a daily
basis. The developing human brain is particularly susceptible
to environmental toxicants, and the damage induced by
neurotoxins can range from onset of neurodevelopment
disorders to long-lasting neurological impairments [45].
With growing awareness and concern regarding the potential
neurotoxicity of environmental contaminants, prescription
drugs, and industrial chemicals, much attention and effort
has been directed towards neurotoxicology.
Neurotoxicology refers to the study of the adverse effects
of chemical, biological, and physical factors on neural func-
tion and development together with their underlying mech-
anisms. Adverse effects can encompass interference with
normal functioning of the nervous system, morphological
changes such as neuronopathy (loss of neurons) or axonopa-
thy (degeneration of nerve axon), andneurochemical changes
[46]. Currently, the overwhelming majority of neurotoxicity
studies reported in the scientific literature rely on either in
vivo animal models or immortalized cell lines as in vitro
models. Experimental data from animal-based studies are
often difficult to interpret due to interspecies differences
in neuroanatomy and neural physiology. For example,
Thalidomide [47, 48] and 13-cis-retinoic acid are well-known
human teratogens, but are innocuous in murine models [49,
50]. Additionally, animal-based neurotoxicity screening is
labor-intensive, expensive, and time consuming, in addition
to being ethically contentious. While immortalized human
neural cell lines are indeed useful for in vitro neurotoxicity
screening, these cell lines derived from tumours invariably
contain chromosomal and genetic aberrations and may not
exhibit the same phenotype as primary cultures of normal
human neurons, astrocytes, and oligodendrocytes [51].
In response to current legislative framework such as the
Registration, Evaluation, and Authorization of Chemicals
(REACH) in the European Union [52] and the need for alter-
native screening tests with higher reliability and effectiveness
to characterize the neurotoxic potential of compounds with-
out the use of live animals, efforts are being directed towards
the development of human pluripotent stem cell-based assays
[53, 54].The application of hPSCs and their neural derivatives
in neurotoxicology assays has many advantages over other
in vitro models, due to the unlimited proliferative potential
of these cells, as well as their ability to recapitulate various
important neurodevelopmental encompassing proliferation,
migration, and differentiation [55].
The embryonic stem cell test (EST) is an existing validated
approach designed by the European Centre for the validation
of alternative methods (ECVAM) to screen compounds for
developmental neurotoxicity [56]. Although this murine-
based EST has proven to be reliable [57], in order to obviate
confusion in data interpretation associated with interspecies
differences, Adler and colleagues [58, 59] pioneered a human-
ized EST and showed the necessity for a human-based system
to detect human-relevant toxicants by demonstrating that
some chemicals display species-specific cytotoxic effects. For
example, 13-cis retinoic acid is cytotoxic to humans but
not to mice. Moreover, they illustrated that marker gene
expression analysis may a useful endpoint for developmental
toxicity screening studies. Currently, there are only a few
studies that have focused specifically on the use of hPSCs
in developmental neurotoxicity. Stummann and colleagues
[60] developed a neurodevelopmental toxicity assay based
on two-step differentiation of hESCs into neural stem cells,
followed by mature neurons. They found that a previously
EST misclassified heavy metal methylmercury (MeHg) com-
pound could disrupt the early stages of neural differentiation
of hESCs. This thus underlined the importance of utilizing
physiologically relevant species-specific toxicology screening
models [60].
Neural stem cells (NSCs) or neural progenitor cells
(NPCs) derived from hPSCs have much potential in the
development of neurotoxicity screening assays. NSCs are
particularly useful for studying chemical interference in
neural differentiation as they are present within a range of
developmental stages of the nervous system and are more
highly sensitive to neurotoxic perturbations, as compared
to other neural lineages [61]. The presence of NSCs in the
discrete neurogenic area of adult brain [62] wouldmake these
cells suited for neurotoxicity studies in the adult nervous
system. In the presence of epidermal growth factor, NSCs
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can develop into free-floating neurospheres, comprising a
heterogeneous mixture of cell lineages. Neurospheres have
been utilised to assess developmental neurotoxicity as these
can recapitulate key processes of human neurodevelopment,
including proliferation, differentiation, andmigration in vitro
[63]. Previous studies have analyzed how neurospheres are
affected by exposure to neurotoxicants by assessing a range
of endpoints such as viability, proliferation, differentiation,
and migration. For example, the exposure of neurospheres
to methylmercury chloride and mercury chloride led to less
differentiation into neural lineages, as well as inhibited cell
migration [63], while exposure to polybrominated diphenyl
ether (PBDE) had negligible cytotoxic effects but significantly
decreased cell migration and neural differentiation during
brain development [64]. Exposure to MeHg also resulted
in significant detrimental effects on neuronal differentiation
[61].
More recently, the advent of induced pluripotent stem
cell (iPSC) technology provides new opportunities for neuro-
toxicology assessment. Utilizing human iPSCs for neurotox-
icology screening assays not only circumvents ethical issues
in the use of pluripotent embryonic stem cells derived from
culled human embryos, but also enables personalised screen-
ing for predicting individual susceptibility to various envi-
ronmental toxicants. There is much evidence in the scientific
literature, which has shown that variation in environmental
and genetic risk factors between individuals may predispose
people to different susceptibility to environmental toxicants
[65]. iPSC lines generated from a wide range of human indi-
viduals with well-characterised adult phenotypes can serve
as model systems for understanding how variation in toxic
susceptibility displayed by different individuals correlates
with their genetics, disease state, and other observable pheno-
types [51]. iPSC lines isolated from patients with neurological
diseases may also help us to understand the relationship
between neurotoxicants and neurological diseases. Disease-
specific iPSC lines allow scientists to examine progression
of neurological diseases and how changes in neural function
elicited by neurotoxicants could be influenced by underlying
genetic inheritance [66].
5. Utilizing Stem Cell Derived
Neurons for Pharmacological Screening and
Drug Development
Neurological and neurodegenerative diseases present poor
prognosis and significant clinical challenges, despite the
tremendous amount of money and effort that have been
invested in drug development research for the treatment of
these diseases. Current treatmentmodalities for neurodegen-
erative diseases are mostly palliative in nature, resulting in
symptomatic relief rather than alteration of disease prognosis,
and there is a dearth of effective medications that slow,
prevent, or reverse the progression of neurodegenerative dis-
eases thus far. Available medications for Alzheimer’s disease
and Parkinson’s disease can only alleviate the symptoms, yet
they are plagued by tolerability issues. The prognoses for
Huntington’s disease and amyotrophic lateral sclerosis are
even bleaker.
A sizable proportion of the ageing population is afflicted
with neurodegenerative diseases and is responsible for the
rising share of morbidity and mortality associated with the
rapidly ageing populations of both developed and developing
countries worldwide. The economic burden of these diseases
is massive, and the human and social costs of caring for these
patients are incalculable. As the global elderly population
is predicted to triple by 2050 [67], the challenges that
neurodegenerative diseases pose to our society will only
increase. Hence, there is an urgent need for new and effective
treatment modalities for neurological diseases.
Drug development is extremely costly and challenging.
The estimated expenditure for a newly developed drug to
reach the market is approximately US $1.5 billion, and this
is expected to continue to skyrocket in the near future
[68]. High rates of late-stage attrition and withdrawals of
candidate drugs have imposed a multi-billion dollar burden
on pharmaceutical companies over the past few decades
and this remains one of the most pressing challenges in
the biopharmaceutical industry [69]. Low efficacy and safety
concerns are the major factors contributing to 90% of lead
compound failures in clinical trials. This is not surprising in
view of the fact that most candidate drug compounds are
only tested on relevant patients in clinical trials. Conventional
drug development has relied heavily on animal-based sys-
tems as human surrogates to evaluate toxicity and efficacy
of candidate drug compounds prior to commencement of
clinical trials. Positive preclinical results observed in animal
models are not necessarily recapitulated in humans owing to
discrepancies in diseasemechanisms and physiology between
animals and humans. The uncertainty of drug translatability
to humans often leads to unexpected failure upon entering
the clinical trial stages, making the drug development project
intractable. In addition, other possible reasons for the failure
of translation from the laboratory bench to clinic in the
development of drugs targeting neurodegenerative diseases
include poor drug penetration due to blood-brain barrier,
problems associated with pharmacokinetics, poor patient
selection criteria, and incorrect end points for measuring
drug effects [41].
Pharmaceutical companies and drug regulatory authori-
ties have been seeking to establish better predicative models
to minimize attrition of candidate drugs at the clinical trial
stages, through early identification of toxicity and adverse
effects of a candidate drug compound, before lengthy and
expensive clinical trials are carried out. It was reported that,
for every 1% increase in predictability of the toxicity of drug
candidate compounds to the human body, a pharmaceutical
company could save up to US $100 million [70]. The emer-
gence of hPSC technology offers access to difficult-to-obtain
human neural cell populations that are more physiologically
and pharmacologically relevant for drug screening. Addi-
tionally, hPSC-derived neurons can overcome many other
pertinent challenges faced in drug development by providing
an unlimited and consistent cell source for high-throughput
screening, thereby saving costs and time, as well as allaying
ethical concerns associatedwith animal testing. Furthermore,
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Table 2: Examples of drug leads screened with hPSCs-derived
neuronal lineages.
Drug lead Disease model Key references
Sulindac sulfide
Compound E
𝛽-secretase
inhibitor IV
Alzheimer’s disease Ebert et al. [74]
Compound W Alzheimer’s disease Yagi et al. [75]
Loxapine Schizophrenia Brennand et al.[73]
Valproic acid Spinal muscularatrophy Ebert et al. [74]
in vitro screening assays based on hPSC-derived neurons can
eliminate patient risk issues and allow the study of drug effect
on multiple cell types derived from the human body, which
could eventually increase the success rates of subsequent
clinical trials [71].
Many studies have reported the use of hiPSCs-derived
neural cells for the drug screening process (Table 2). Yahata
et al. [72] generated hiPSCs-derived amyloid 𝛽-secreting
neurons expressing functional 𝛽- and 𝛾-secretase and uti-
lized these cells to screen for novel effective anti-amyloid
𝛽 drugs against Alzheimer’s disease. Moreover, disease-
specific hiPSCs are useful in assessing the effects of novel
therapeutic compounds, resulting in a greater likelihood of
positive efficacy in humans. For example, Brennand et al.
[73] reprogrammed fibroblasts from Schizophrenia (SCZD)
patients into hiPSCs and subsequently differentiated these
into neurons.These hiPSCs-derived neurons express disease-
specific phenotypes, including decreased neuronal connec-
tivity and differential gene expression patterns in the cAMP
and WNT signalling pathways. It was observed that the
neuronal activity of SCZD neurons was improved following
treatment with the antipsychotic drug Loxapine. Another
study demonstrated that application of valproic acid (VPA)
and tobramycin in a spinal muscular atrophy (SMA) neuron
model established from hiPSCs could upregulate expression
of survival motor neuron (SMN) protein [74]. In addition,
Yagi et al. [75] have identified a promising drug candidate
for Alzheimer’s disease therapy by screening with hPSC-
derived neurons. The aberrantly increased amyloid 𝛽42
secretion attributed tomutant presenilin inAD-iPSC-derived
neurons was reduced by treating with compound W (𝛾-
secretase inhibitor and modulator), indicating the potential
of compoundW as a therapeutic drug [75].
Considering the available evidence in the scientific lit-
erature, we can conclude that hPSC technology indeed
provides a powerful tool for pharmacological screening and
drug development, bridging the translational gap from the
laboratory to clinical trials, as well as presenting an excellent
and cost effective in vitro drug screening system to overcome
current challenges faced by the biopharmaceutical industry.
Furthermore, iPSC technology could be applied to disease-
and patient-specific studies to elucidate individual variations
in pharmacokinetics and pharmacodynamics, thereby facili-
tating the development of personalised medicine [76].
Although promising, there are many hurdles to be over-
come in the application of hPSC technology in pharmaco-
logical assays. The growth and expansion of hPSCs are tech-
nically demanding and require greater expertise than other
commonly utilized cell types for in vitro screening assays. For
example, the culture of hPSCs requires constant monitoring
and manual purging of spontaneously differentiated cells.
Additionally, it is necessary to assess iPSC clones from the
samepatient for consistent genotypes andphenotypes, as they
may acquire undesirable genetic and epigenetic alterations
during the reprogramming process [77–79].Their propensity
to differentiate into various lineages needs to be analysed, as
adult somatic cell-derived iPSCsmay preserve some degree of
epigenetic memory of their past and therefore exhibit biased
differentiation propensity to their somatic lineage of origin
[80, 81]. For in vitro screening assays, it is imperative that
an optimized differentiation protocol for hPSCs developed to
derive a population of homogeneous and stable neural cells.
Rigorous characterisation of intermediate and terminally
differentiated populations is essential for the establishment of
highly specialised cellular models with better reproducibility
and consistency, which could serve as a high-predictivity
drug screening tool. Given the ongoing intensive efforts of
research laboratories and pharmaceutical industries to estab-
lish safer and more efficient protocols in hPSC technology,
there is cause for optimism that hPSC technology will be
applied broadly in the drug development pipeline in the near
future and may ultimately contribute to the discovery of new
cures for neurological diseases with currently poor clinical
prognosis.
6. In Vitro Modeling of Neurodegenerative
and Neurodevelopmental Diseases
As mentioned previously, animal models to study neurologi-
cal diseases have inherent limitations and disadvantages and
do not fully recapitulate the human neural phenotype. Hence,
iPSCs may provide a vital tool for the study of human neu-
rodegenerative and neurodevelopmental diseases (Table 3)
through their differentiation into functional neurons in a
controlled in vitro environment [82]. Neurodegeneration
refers to the gradual deterioration of cognitive abilities due
to structural changes that prevents neurons from functioning
normally [83], whereas neurodevelopmental disorders are
characterized by impairment of neuronal function during
brain development which adversely affects emotions, self-
control, learning ability, and memory of an individual.
Amongst the most notable and frequently occurring
neurodegenerative diseases are Alzheimer’s disease, Parkin-
son’s disease, Huntington’s disease, and amyotrophic lateral
sclerosis [83]. Typically, these diseases are characterized
by being age-related [83] meaning that neurons gradu-
ally lose their function as these neurodegenerative diseases
progress with age. Currently, reprogramming technology
allows researchers to study the development and progression
of neurodegeneration in a human system and thismay in turn
enables the development of new early diagnostic technologies
and improved treatment modalities.
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Table 3: In vitromodeling of neurodegenerative and neurodevelop-
mental disorders with hPSCs-derived neuronal lineages.
Disease model Key references
Alzheimer’s disease Israel et al. [84]
Huntington’s disease An et al. [85]The HD iPSC Consortium [86]
Amyotrophic lateral sclerosis Mitne-Neto et al. [87]
Autism spectrum disorder Kim et al. [88]
Schizophrenia Chiang et al. [89]Brennand et al. [90]
Rett syndrome
Ananiev et al. [91]
Cheung et al. [92]
Li et al. [93]
Williams et al. [94]
Fragile X syndrome
Sheridan et al. [95]
Bar-Nur et al. [96]
Liu et al. [97]
Timothy syndrome Pas¸ca et al. [98]Krey et al. [99]
Alzheimer’s disease is the most common type of age-
related dementia found in aging population and is the 6th
leading cause of death in USA [100]. Clinically, the disease
is characterized by progressive memory loss and decline in
cognitive abilities [101]. Alzheimer’s disease can be caused by
mutations in presenilin- (PS-) 1, PS2, or amyloid precursor
protein (APP), as well as microtubule-associated protein
tau [102]. These mutations are inherited in an autosomal
dominant manner and are thus referred to as familial
Alzheimer’s disease [102]. Israel and colleagues [84] demon-
strated that iPSC-derived neurons from patients with APP
duplications have elevated amyloid 𝛽40 and patients with
sporadic Alzheimer’s disease can have increased amyloid 𝛽40
expression and enlarged endosomes [84]. Additionally, they
also observed increased expression of phosphorylated Tau,
the precursor to neurofibrillary tangle formation, besides
elevated amyloid 𝛽.
Huntington’s disease is another progressive neurode-
generative disorder. It is caused by an elongated stretch
of a triplet-repeat CAG (coding for glutamine) within the
huntingtin gene on chromosome 4 [103]. This repeating of
CAG results in a polyglutamine domain [104]. Because it is
caused by mutations in a single gene, several groups have
attempted to model Huntington’s disease with iPSCs derived
from Huntington’s disease patients [85, 86]. An et al. [85]
reported that neural stem cells derived from Huntington’s
disease hiPSCs were more susceptible to oxidative stress than
normal iPSCs.This was overcome when Huntington’s disease
iPSC CAG repeat was corrected by genetic engineering
[85]. Huntington’s disease consortium reported that NSCs
with higher CAG repeat failed to develop into functional
neurons and gradually died off, unlike NSCs with lower CAG
repeats [86]. In addition, distinct morphological changes
associated with neural progenitor cells (NPC) derived from
Huntington’s disease iPSC lines were also observed [86].
Amyotrophic lateral sclerosis is a progressive fatal disease
that basically affects both upper and lower motor neurons,
resulting in dysfunction and death of the affected neurons
[105]. Amyotrophic lateral sclerosis is caused by mutations
in superoxide dismutase 1 (SOD1) enzyme [106] and vamp-
associated protein B/C (VAPB) [107]. Mitne-Neto et al.
[87] studied iPSCs lines from amyotrophic lateral sclerosis
patients with mutations on the VAPB gene as well as from
their unaffected siblings as controls. They showed a signifi-
cant reduction in VAPB protein levels in amyotrophic lateral
sclerosis iPSC-derived motor neurons but could not detect
any cytoplasmic aggregation [87].
In neurodevelopmental disorders, iPSCs-based models
can recapitulate the early steps of neuronal differentiation
known to result in these pathologies and can facilitate the
study of the cellular and molecular causes of these disorders.
Recently, several groups have used hPSCs to model other
less common neurodevelopmental disorders such as autism
spectrum disorder (ASD) [88], schizophrenia (SCZD) [89,
90], Rett syndrome (RTT) [91–94], fragile X syndrome [95–
97], and Timothy syndrome [98, 99].
Several studies have thus shown that iPSCs technology
has much potential for investigating the molecular mech-
anisms of an array of neurological diseases that currently
have no cure. Modeling neurodegenerative and neurodevel-
opmental diseases using this technology can possibly have
a significant impact on the development of new therapeutic
modalities for these diseases.
7. Conclusion and Future Outlook
Despite some lingering doubts that iPSCs are not exactly
identical to hESCs [108], iPSC technology has largely cir-
cumvented ethical obstacles previously associated with hESC
research and is gradually supplanting hESC as an important
tool for in vitromodeling of human neurological diseases and
developing drug screening systems, identifying therapeutic
targets, in addition to providing autologous cell sources for
therapy of various neurological diseases [76, 82, 109–111]. A
promising nontherapeutic application of PSCs that has yet to
be developed is for in vitro study and modeling of infectious
diseases that specifically target the nervous system such as
Nipah virus, Japanese encephalitis, and Rabies [112]. This is
anticipated to be realized in the near future.
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